as a preliminary matter , it will readily be understood by one having ordinary skill in the relevant art (“ ordinary artisan ”) that the present invention has broad utility and application . furthermore , any embodiment discussed and identified as being “ preferred ” is considered to be part of a best mode contemplated for carrying out the present invention . other embodiments also may be discussed for additional illustrative purposes in providing a full and enabling disclosure of the present invention . moreover , many embodiments , such as adaptations , variations , modifications , and equivalent arrangements , will be implicitly disclosed by the embodiments described herein and fall within the scope of the present invention . accordingly , while the present invention is described herein in detail in relation to one or more embodiments , it is to be understood that this disclosure is illustrative and exemplary of the present invention , and is made merely for the purposes of providing a full and enabling disclosure of the present invention . the detailed disclosure herein of one or more embodiments is not intended , nor is to be construed , to limit the scope of patent protection afforded the present invention , which scope is to be defined by the claims and the equivalents thereof . it is not intended that the scope of patent protection afforded the present invention be defined by reading into any claim a limitation found herein that does not explicitly appear in the claim itself . thus , for example , any sequence ( s ) and / or temporal order of steps of various processes or methods that are described herein are illustrative and not restrictive . accordingly , it should be understood that , although steps of various processes or methods may be shown and described as being in a sequence or temporal order , the steps of any such processes or methods are not limited to being carried out in any particular sequence or order , absent an indication otherwise . indeed , the steps in such processes or methods generally may be carried out in various different sequences and orders while still falling within the scope of the present invention . accordingly , it is intended that the scope of patent protection afforded the present invention is to be defined by the appended claims rather than the description set forth herein . additionally , it is important to note that each term used herein refers to that which the ordinary artisan would understand such term to mean based on the contextual use of such term herein . to the extent that the meaning of a term used herein — as understood by the ordinary artisan based on the contextual use of such term — differs in any way from any particular dictionary definition of such term , it is intended that the meaning of the term as understood by the ordinary artisan should prevail . furthermore , it is important to note that , as used herein , “ a ” and “ an ” each generally denotes “ at least one ,” but does not exclude a plurality unless the contextual use dictates otherwise . thus , reference to “ a picnic basket having an apple ” describes “ a picnic basket having at least one apple ” as well as “ a picnic basket having apples .” in contrast , reference to “ a picnic basket having a single apple ” describes “ a picnic basket having only one apple .” when used herein to join a list of items , “ or ” denotes “ at least one of the items ,” but does not exclude a plurality of items of the list . thus , reference to “ a picnic basket having cheese or crackers ” describes “ a picnic basket having cheese without crackers ”, “ a picnic basket having crackers without cheese ”, and “ a picnic basket having both cheese and crackers .” finally , when used herein to join a list of items , “ and ” denotes “ all of the items of the list .” thus , reference to “ a picnic basket having cheese and crackers ” describes “ a picnic basket having cheese , wherein the picnic basket further has crackers ,” as well as describes “ a picnic basket having crackers , wherein the picnic basket further has cheese .” referring now to the drawings , in which like numerals represent like components throughout the several views , the preferred embodiments of the present invention are next described . the following description of the preferred embodiment ( s ) is merely exemplary in nature and is in no way intended to limit the invention , its application , or uses . fig2 and 3 are a side view and a side cross - sectional view of a hypodermic syringe 10 in accordance with one or more preferred embodiments of the present invention . it will be appreciated that , for the sake of clarity , the syringe 10 of fig2 is shown as being at least partially transparent , wherein broken lines are used to indicate interior surfaces . with reference to both fig2 and 3 , the syringe 10 may be constructed generally conventionally , with a barrel 20 , a plunger assembly 30 and a hollow needle 18 . the barrel 20 defines an interior cylinder 22 within which the plunger assembly 30 is fitted . the plunger assembly 30 includes a piston 32 , a rubber gasket 34 and a handle 36 extending from one end of the barrel 20 . the hollow needle 18 is coupled , preferably removably such as via a hand - tightened threaded fitting such as a luer lock , to the opposite end of the barrel 20 , and the interior of the needle 18 is in fluid communication with the interior of the barrel 20 . as a safety precaution , the needle 18 is typically covered with a removable cap ( not shown ) when not in use . notably , the barrel 20 of the syringe 10 of fig2 and 3 is marked in increments of dosage units rather than in hundredths of ml , as in the conventional syringe of fig1 . in particular , as shown in fig2 , the barrel 20 has increments totaling 50 units . if the syringe 10 is a 1 ml syringe ( i . e ., of the same volume as the syringe of fig1 ), then the syringe 10 shown in fig2 is to be understood to have , and should preferably only be used with , a dosage concentration of 50 units (“ u ”)/ 1 ml . fig4 , on the other hand , is a side view of a hypodermic syringe 110 that is generally similar to that of fig2 but is marked in different dosage unit increments . in particular , the barrel 120 has increments totaling 40 units . if the syringe 110 is a 1 ml syringe ( i . e ., of the same volume as the syringe of fig1 and as the syringe 10 of fig2 ), then the syringe 110 shown in fig4 is to be understood to have , and should preferably only be used with , a dosage concentration of 40 units (“ u ”)/ 1 ml . the barrel 20 may also be marked to indicate the concentration level of the solution in the syringe 10 , i . e , the amount of diluent that is used to reconstitute the drug . the capacity may be marked by printing a number 42 , a code 44 ( such as a number of rings ), or the like , representative of the concentration ( in u / ml ) of the syringe 10 , on the barrel 20 thereof . for example , the number 42 , code 44 , or the like may directly indicate the amount of diluent used to reconstitute 100 units of the drug . in one such implementation , a “# 1 ” syringe ( marked “ 1 ” and / or having one ring around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 1 ml of saline for every 100 units of the drug , a “# 2 ” syringe ( marked “ 2 ” and / or having two rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 2 ml of saline for every 100 units of the drug , a “# 3 ” syringe ( marked “ 3 ” and / or having three rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 3 ml of saline for every 100 units of the drug , a “# 4 ” syringe ( marked “ 4 ” and / or having four rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 4 ml of saline for every 100 units of the drug , and a “# 5 ” syringe ( marked “ 5 ” and / or having five rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 5 ml of saline for every 100 units of the drug . in this example , it will be appreciated that a # 1 1 ml syringe , if fully drawn up , would thus contain 100 units of the drug , a # 2 1 ml syringe , if fully drawn up , would thus contain 50 units of the drug , a # 3 1 ml syringe , if fully drawn up , would thus contain 33 units of the drug , a # 4 1 ml syringe , if fully drawn up , would thus contain 25 units of the drug , and a # 5 1 ml syringe , if fully drawn up , would thus contain 20 units of the drug . two such syringes are illustrated in fig5 a and 5b , wherein the syringe 210 in fig5 a has a “ 4 ” printed near one end of the barrel 220 and 4 rings printed near the opposite end of the barrel 220 and thus contains a concentration of 4 ml of diluent per 100 units of the drug , while the syringe 310 in fig5 b has a “ 2 ” printed near one end of the barrel 320 and 2 rings printed near the opposite end of the barrel 320 and thus contains a concentration of 2 ml of diluent per 100 units of the drug . in another such implementation , an “ a ” syringe ( marked “ a ” and / or having one ring around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 1 . 0 ml of saline for every 100 units of the drug , a “ b ” syringe ( marked “ b ” and / or having two rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 2 . 0 ml of saline for every 100 units of the drug , a “ c ” syringe ( marked “ c ” and / or having three rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 2 . 5 ml of saline for every 100 units of the drug , a “ d ” syringe ( marked “ d ” and / or having four rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 4 . 0 ml of saline for every 100 units of the drug , and an “ e ” syringe ( marked “ e ” and / or having five rings around the barrel ) may indicate that the drug in the syringe has been reconstituted or diluted at a concentration of 8 . 0 ml of saline for every 100 units of the drug . in this example , it will be appreciated that a 1 ml “ a ” syringe , if fully drawn up , would thus contain 100 units of the drug , a 1 ml “ b ” syringe , if fully drawn up , would thus contain 50 units of the drug , a 1 ml “ c ” syringe , if fully drawn up , would thus contain 40 units of the drug , a 1 ml “ d ” syringe , if fully drawn up , would thus contain 25 units of the drug , and a 1 ml “ e ” syringe , if fully drawn up , would thus contain 12 . 5 units of the drug . alternatively , the markings ( number 42 , rings 44 , or the like ) may be used to more directly indicate the number of units contained in the syringe 10 , 110 , 210 , 310 . color - coding may also be utilized on one or more parts of the syringe 10 , 110 , 210 , 310 to make it easier to distinguish , both for those reconstituting the drug and for those drawing up the syringe 10 , 110 , 210 , 310 , the number of units that are or should be contained therein . for example , all or portions of the barrel 20 , 120 , 220 , 320 , the plunger handle 36 , and / or the cap over the needle 18 may be made of colored material or otherwise colored in some way based on the capacity of the syringe 10 , 110 , 210 , 310 , the number of units contained therein , or the like . the colors may likewise be coordinated with printed material included on charts , instructions , packaging , or the like in order to established a uniform , easily - followed guide for reconstitution and use of the drug and the syringe 10 , 110 , 210 , 310 . in one such implementation , a “# 1 ” syringe includes a red plunger handle and needle cap , a “# 2 ” syringe includes an orange plunger handle and needle cap , a “# 3 ” syringe includes a yellow plunger handle and needle cap , a “# 4 ” syringe includes a green plunger handle and needle cap , a “# 5 ” syringe includes a blue plunger handle and needle cap , and accompanying packaging and printed instructions include color - coordination information and indicia to help the user utilize each syringe properly such that the concentrations described previously for # 1 , # 2 , # 3 , # 4 and # 5 syringes are drawn up in each one . information about the chosen color coding system may also be disseminated to patients so that they may readily recognize , understand and use the proper concentration , and thus the proper number of units of the drug . in at least one embodiment , the barrel 20 , 120 , 220 , 320 , the plunger handle 36 , and the cap are marked with the generic name and / or the brand name of the drug in order to assure that the syringe 10 , 110 , 210 , 310 is assembled properly and used with the proper drug . the dimensions of the syringe 10 , 110 , 210 , 310 are chosen so that a sufficient volume of injectable fluid may be drawn up within the interior cylinder 22 for administration to a patient . the barrel 20 , 120 , 220 , 320 of the syringe 10 , 110 , 210 , 310 may be constructed of any conventional syringe material , including glass , polyethylene , polycarbonate , or polyvinyl or other synthetic polymer or various other plastics , and is preferably transparent or translucent such that the fluid or plunger assembly 30 may be viewed within . the plunger assembly 30 is likewise constructed from any suitable inert material including , but not limited to , plastic , vinyl , polyethylene , rubber , platinum - cured silicon or teflon ®. in at least one embodiment , the interior volume of the syringe 10 , 110 , 210 , 310 is slightly more than 1 ml such that an amount of substantially exactly 1 ml of injectable fluid may be contained therein . however , it will be appreciated that other volumes may likewise be utilized . fig6 is a flowchart illustrating the steps of a method of use 600 in accordance with one or more preferred embodiments of the present invention . the method 600 begins at step 605 with the receipt , by a medical practitioner , facility , organization of the like of an injectable drug , medicine or the like in dry , reconstitutable form . such injectable drugs or medicines are often provided in vacuum - dried form , and include , without limitation , botulinum toxin type a ( sold or planning to be sold under the trade names botox ®, dysport ®, reloxin ™ and puretox ™) and botulinum toxin type b ( sold under the trade name myobloc ®), both frequently administered for the treatment of facial wrinkles botox , for example , is typically supplied in vials containing 100 units of botox in dry form . such dry - form drugs may often be reconstituted in a variety of concentrations , often depending on practitioner preference . for example , botox is commonly reconstituted in concentrations of 1 . 0 ml of diluent ( typically nonpreserved normal saline , or 0 . 9 % sodium chloride injection ) per 100 units of botox for a dosage concentration of 10 . 0 u of botox per 0 . 1 ml ( 100 u / 1 ml ), 2 . 0 ml of diluent per 100 units of botox for a dosage concentration of 5 . 0 u of botox per 0 . 1 ml ( 50 u / 1 . 0 ml ), 2 . 5 ml of diluent per 100 units of botox for a dosage concentration of 4 . 0 u of botox per 0 . 1 ml ( 40 u / 1 ml ), 4 . 0 ml of diluent per 100 units of botox for a dosage concentration of 2 . 5 u of botox per 0 . 1 ml ( 25 u / 1 ml ), or 8 . 0 ml of diluent per 100 units of botox for a dosage concentration of 1 . 25 u of botox per 0 . 1 ml ( 12 . 5 u / 1 ml ). at step 510 , a desired reconstitution concentration is selected . preferably , the concentration is selected according to a particular policy , e . g ., a particular medical facility may have a policy of providing all dosages in a concentration of 50 u / 1 ml , or according to a particular prescription , e . g ., a practitioner may prescribe use of a concentration of 40 u / 1 ml . at step 615 , a desired number of units may be reconstituted according to the desired dosage concentration . perhaps most conveniently , an entire vial of the vacuum - dried drug may be reconstituted at once , but portions of vials may in some cases be reconstituted , or multiple vials are reconstituted at once . reconstitution may be carried out according to conventional procedures , and care should be taken to ensure that the proper concentration is achieved and properly labeled or otherwise tracked before being drawn up into individual syringes . based on the dosage concentration present in the injectable fluid , one or more corresponding syringe is selected at step 620 for use therewith . more particularly , a syringe , such as the hypodermic syringe 10 of fig2 , having unit markings corresponding with the dosage concentration is selected for use with the dosage concentration . care should be taken to ensure that only a properly - marked syringe is utilized for each particular dosage concentration . the syringe 10 in fig2 , for example , is labeled for use with a dosage concentration of 50 u / 1 ml , and thus should only be used for an injectable fluid having a dosage concentration of 50 u / 1 ml . on the other hand , the syringe 110 in fig4 is labeled for use with a dosage concentration of 40 u / 1 ml , and thus should only be used for an injectable fluid having a dosage concentration of 40 u / 1 ml . it is also recognized that different drugs are provided by different manufacturers in different standard units . for example , although botox and dysport are very similar , botox is commonly provided by the manufacturer in 100 - unit packages or increments , while dysport is commonly provided by the manufacturer in 300 - unit packages or increments , and the relative units are not necessarily equivalent . thus , to help ensure that reconstituted units of a drug are drawn up or otherwise utilized with a syringe that is properly calibrated for that drug , each syringe may be marked with an indication of the drug manufacturer with which the syringe is to be used , with an indication of the standard number of units in which the drug is to be used , or both . for example , fig7 is a side view of a hypodermic syringe 410 similar to that of fig2 but marked with a manufacturing source identifier 446 and an indication 448 of the unit measure . in particular , the manufacturing source identifier 446 on the syringe 410 in fig7 indicates that the syringe 410 is to be used with botox ®, which is manufactured by ( or possibly under license from ) allergan , inc . of irvine , calif ., and the unit measure indication 448 on the syringe 410 in fig7 indicates that the syringe 410 is to be used with a drug , such as botox ®, that is supplied in 100 - unit increments ( rather than , for example , a drug , such as dysport ®, that is supplied in 300 - unit increments . selection of a syringe based on manufacturing source identifier 446 , unit measure indication 448 , or both may be incorporated into step 620 . using the proper syringe 10 , 110 , 210 , 310 , 410 an amount of the injectable fluid corresponding to a desired number of units of the drug may be drawn up at step 625 . for example , fig8 is a side view of the hypodermic syringe 10 of fig2 , shown with a full 50 units drawn up therein . finally , a desired number of units ( which may be some or all of the units that have been drawn up ) are administered at each injection site at step 630 . advantageously , assuming the proper concentration is prepared , the syringes and methods of use of the present invention help to ensure that each syringe is drawn up with the proper concentration of drug . also advantageously , assuming the proper concentration is prepared and properly drawn into the syringe , the syringes and methods of use of the present invention help to ensure that the proper dosage of the drug is injected . also advantageously , assuming the proper concentration is prepared and properly drawn into the syringe , the syringes and methods of use of the present invention help to ensure that the patient receives the proper number of units of the drug . overall , although the present invention cannot prevent an individual from intentionally preparing the wrong concentration or utilizing the wrong syringe for the reconstituted drug , the syringes and methods of use of the present invention advantageously help to avoid accidental errors of these types . based on the foregoing information , it is readily understood by those persons skilled in the art that the present invention is susceptible of broad utility and application . many embodiments and adaptations of the present invention other than those specifically described herein , as well as many variations , modifications , and equivalent arrangements , will be apparent from or reasonably suggested by the present invention and the foregoing descriptions thereof , without departing from the substance or scope of the present invention . accordingly , while the present invention has been described herein in detail in relation to its preferred embodiment , it is to be understood that this disclosure is only illustrative and exemplary of the present invention and is made merely for the purpose of providing a full and enabling disclosure of the invention . the foregoing disclosure is not intended to be construed to limit the present invention or otherwise exclude any such other embodiments , adaptations , variations , modifications or equivalent arrangements ; the present invention being limited only by the claims appended hereto and the equivalents thereof . although specific terms are employed herein , they are used in a generic and descriptive sense only and not for the purpose of limitation .
a method of reconstituting and administering an injectable fluid distributed to practitioners in dry - form includes receiving a drug or medicine in dry form , selecting a reconstitution concentration for the drug or medicine , reconstituting a desired number of units of the drug or medicine by adding diluent to the dry - form drug or medicine , selecting a syringe having units marked according to the selected reconstitution concentration , drawing up a desired number of drug or medicine units using the selected syringe , and administering a desired number of units according to the unit markings on the selected syringe . such a syringe includes a barrel , a plunger assembly that has a plunger handle and a piston , a needle , and a needle cap . the syringe includes a visual indicia , representing a first drug concentration contained in the barrel , that is distinguishable from a corresponding visual indicia , on a second syringe , representing a second drug concentration .